https://www.prognyx.com/blog/abbvie-files-fda-application-for-etentamig-its-bcma-bispecific-for-myelomaPrognyxen2026-10-30AbbVie files FDA application for etentamig, its BCMA bispecific for myeloma https://www.prognyx.com/blog/j-j-s-rybrevant-faspro-posts-77-response-rate-in-first-line-head-and-neck-cancerPrognyxen2026-10-29J J's RYBREVANT FASPRO posts 77% response rate in first-line head and neck cancer